Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Pharmacological profile of the novel, selective kappa-opioid agonist HZ2

Nov. 12, 1998

Preparation and use of new CNS-active series reported by Pharmacia & Upjohn

Nov. 12, 1998

Improved dosage form of selegiline now on the U.K. market

Nov. 11, 1998

Neuroprotective effects of NCC-161, a new neuronal calcium antagonist

Nov. 11, 1998

Synthelabo presents new 5-HT1A inverse agonist with antagonist and anxiolytic-like activity in vivo

Nov. 11, 1998

PD-161989: novel AMPA/GLYN receptor antagonist related to PNQX

Nov. 11, 1998

Chugai describes inhibitors of iNOS, nNOS

Nov. 11, 1998

Synthelabo presents in vitro, ex vivo and in vivo data on new MAO-B inhibitor

Nov. 11, 1998

LY-300164 protects against kainate-induced neurotoxicity in vitro in a stereoselective manner

Nov. 11, 1998

Nonpeptide CRF1 antagonist developed at Parke-Davis modulates brain NE levels

Nov. 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...